MVT-100: Advancing the Clinical Use of Perflutren Ultrasound Contrast Agents for Suboptimal Echocardiograms
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Perflutren (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Microvascular Therapeutics
- 30 Mar 2023 Status changed from active, no longer recruiting to recruiting.
- 30 Mar 2023 Planned End Date changed from 31 Mar 2022 to 31 Dec 2024.
- 30 Mar 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2024.